Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19

Henry C. Cousins, Adrienne Sarah Kline, Chengkun Wang, Yuanhao Qu, Mengdi Wang, Russ B. Altman, Yuan Luo, Le CongmedRxiv 2022 · DOI

Abstract

Treatment strategies that target host entry factors have proven an effective means of impeding viral entry in HIV and may be more robust to viral evolution than drugs targeting viral proteins directly. High-throughput functional screens provide an unbiased means of identifying genes that influence the infection of host cells, while retrospective cohort analysis can measure the real-world, clinical potential of repurposing existing therapeutics as antiviral treatments. Here, we combine these two powerful methods to identify drugs that alter the clinical course of COVID-19 by targeting host entry factors. We demonstrate that integrative analysis of genome-wide CRISPR screening datasets enables network-based prioritization of drugs modulating viral entry, and we identify three common medications (spironolactone, quetiapine, and carvedilol) based on their network proximity to putative host factors. To understand the drugs’ real-world impact, we perform a propensity-score-matched, retrospective cohort study of 64,349 COVID-19 patients and show that spironolactone use is associated with improved clinical prognosis, measured by both ICU admission and mechanical ventilation rates. Finally, we show that spironolactone exerts a dose-dependent inhibitory effect on viral entry in a human lung epithelial cell line. Our results suggest that spironolactone may improve clinical outcomes in COVID-19 through tissue-dependent inhibition of viral entry. Our work further provides a potential approach to integrate functional genomics with real-world evidence for drug repurposing.

Introduction

Traditional antiviral strategies frequently target viral proteins, such as the SARS-CoV-2 Spike protein. However, the rapid mutation rate of viruses often leads to the emergence of variants that can escape these treatments. A more robust alternative is to target host entry factors—the stable human proteins that viruses hijack to enter cells. Because human genes do not mutate at the rate of viral genomes, targeting these "gatekeepers" offers a more resilient therapeutic approach.

The primary challenge in this field is identifying which of the thousands of human genes are the most critical for viral entry and determining which FDA-approved drugs can safely modulate them. While individual genetic screens provide insights, they are often noisy and context-dependent. This study addresses these challenges by integrating functional genomics with large-scale clinical data to identify and validate repurposed drugs for COVID-19.

Methodology

The researchers developed a three-stage integrative pipeline to bridge the gap between laboratory screens and clinical outcomes:

1. Network-Based Prioritization

Rather than relying on a single experiment, the team integrated data from eight different genome-wide CRISPR screens (including both knock-out and activation screens) across various human cell lines (HuH-7, A549, Calu-3, and HEK293T). They constructed a bipartite graph connecting identified genes to FDA-approved compounds via the DrugBank database. Drugs were ranked using Normalized Degree Centrality (NDC), prioritizing compounds that interact with the highest number of identified viral entry factors across multiple screens.

2. Retrospective Clinical Analysis

To evaluate the real-world efficacy of the top network hits, the study utilized de-identified electronic health records (EHR) from 64,349 unique COVID-19 patients within the Northwestern Medicine Electronic Data Warehouse. To ensure a fair comparison, they employed Propensity Score Matching (PSM), creating a control group with nearly identical health profiles—including age, race, and comorbidities like hypertension and diabetes—to those taking the candidate drugs.

3. In Vitro Validation

Finally, the top candidate, spironolactone, was tested in a laboratory setting. Researchers performed a pseudoviral entry assay using human lung epithelial cells to determine if the drug physically inhibited the virus's ability to enter cells in a dose-dependent manner.

Key Insights

The Power of Data Integration

While individual CRISPR screens showed variable correlation, the network-level analysis revealed shared pathways that were consistently enriched across experiments. Specifically, pathways involving glycosaminoglycans and phosphoglycerides were highlighted as essential for viral attachment, demonstrating that network integration can filter out experimental noise to find core biological mechanisms.

Spironolactone’s Multi-Pronged Mechanism

Spironolactone, a common diuretic, emerged as a top candidate due to its interaction with multiple host factors. It modulates androgen signaling proteins (such as TMPRSS2) and voltage-gated cation channels. Beyond blocking viral entry, the authors suggest spironolactone may help mitigate the electrolyte imbalances, such as hypokalemia and hypocalcemia, frequently observed in severe COVID-19 cases.

Results

Network and Clinical Findings

The analysis identified 33 drugs as significant hits across at least three genetic screens. Among those with sufficient clinical data for evaluation, spironolactone, quetiapine, and carvedilol were the most prominent.

Clinical validation revealed that spironolactone use was associated with a significant reduction in ICU admissions (Odds Ratio 0.42; p = 0.004). It also showed a strong negative association with the need for mechanical ventilation (OR 0.31), although this result narrowly missed the threshold for statistical significance (p = 0.052).

Laboratory Validation

In vitro assays confirmed that spironolactone exerts a dose-dependent inhibitory effect on viral entry 24 hours post-infection. While a transient increase in entry was noted at 4 hours for the highest doses, the long-term steady-state effect was a significant decrease in viral infection.

Discussion and Limitations

This study provides a roadmap for integrating functional genomics with real-world evidence. However, several limitations remain. The clinical analysis was conducted within a single healthcare system, and as an observational retrospective study, it establishes association rather than definitive causation. Furthermore, the laboratory validation utilized a pseudotyped virus rather than live SARS-CoV-2.

Future work should focus on multi-center studies and well-powered randomized controlled trials (RCTs) to confirm the therapeutic role of spironolactone. Nevertheless, these findings suggest that spironolactone may improve clinical outcomes in COVID-19 through tissue-dependent inhibition of viral entry, offering a promising, low-cost tool in the ongoing effort to manage the pandemic.

Summary updated

Abstract

ABSTRACT Treatment strategies that target host entry factors have proven an effective means of impeding viral entry in HIV and may be more robust to viral evolution than drugs targeting viral proteins directly. High-throughput functional screens provide an unbiased means of identifying genes that influence the infection of host cells, while retrospective cohort analysis can measure the real-world, clinical potential of repurposing existing therapeutics as antiviral treatments. Here, we combine these two powerful methods to identify drugs that alter the clinical course of COVID-19 by targeting host entry factors. We demonstrate that integrative analysis of genome-wide CRISPR screening datasets enables network-based prioritization of drugs modulating viral entry, and we identify three common medications (spironolactone, quetiapine, and carvedilol) based on their network proximity to putative host factors. To understand the drugs’ real-world impact, we perform a propensity-score-matched, retrospective cohort study of 64,349 COVID-19 patients and show that spironolactone use is associated with improved clinical prognosis, measured by both ICU admission and mechanical ventilation rates. Finally, we show that spironolactone exerts a dose-dependent inhibitory effect on viral entry in a human lung epithelial cell line. Our results suggest that spironolactone may improve clinical outcomes in COVID-19 through tissue-dependent inhibition of viral entry. Our work further provides a potential approach to integrate functional genomics with real-world evidence for drug repurposing.
BibTeX
@misc{cousins2022integrative,
  author = {Henry C. Cousins and Adrienne Sarah Kline and Chengkun Wang and Yuanhao Qu and Mengdi Wang and Russ B. Altman and Yuan Luo and Le Cong},
  title = {{Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19}},
  year = {2022},
  doi = {10.1101/2022.07.02.22277181},
  howpublished = {medRxiv},
}
Figure